Navigation Links
Abbott's XIENCE(TM) V Drug Eluting Stent Demonstrates Consistent and Positive Clinical Outcomes Out to Two Years
Date:3/31/2008

- New Data from SPIRIT II Show Continued Low Rates of MACE with XIENCE V -

CHICAGO, March 31 /PRNewswire-FirstCall/ -- Data presented today from Abbott's SPIRIT II clinical trial demonstrated continued positive clinical results for the XIENCE(TM) V Everolimus Eluting Coronary Stent System out to two years, including an observed 40 percent reduction in major adverse cardiac events (MACE) and an observed 44 percent reduction in vessel retreatment (ischemia-driven target lesion revascularization, TLR) compared to the TAXUS(R) paclitaxel-eluting coronary stent system. The two-year results from the SPIRIT II trial were presented at the SCAI Annual Scientific Sessions in Partnership with ACC i2 Summit.

SPIRIT II is a 300-patient randomized clinical trial, which was conducted in Europe and Asia Pacific to support the launch of XIENCE V outside the United States. In SPIRIT II, XIENCE V demonstrated the following key results:

-- In an analysis of major adverse cardiac events (MACE), XIENCE V

demonstrated an observed 40 percent reduction in MACE compared to

TAXUS at two years (6.6 percent for XIENCE V vs. 11.0 percent for

TAXUS). MACE is an important clinical measure of patient outcomes,

defined as cardiac death, heart attack (myocardial infarction or MI),

or ischemia-driven target lesion revascularization.

-- XIENCE V demonstrated an observed 44 percent reduction in

ischemia-driven target lesion revascularization (TLR driven by lack of

blood supply) compared to TAXUS at two years (3.8 percent for XIENCE V

vs. 6.8 percent for TAXUS).

-- Rates of definite/probable stent thrombosis under the Dublin/Academic

Research Consortium (ARC) definition were 0.9 percent for XIENCE V and

1.4 percent for TAXUS at two years. The ARC definition of late-stent

thrombosis was developed to eliminate variability in the definitions

across various
'/>"/>

SOURCE Abbott
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Abbotts XIENCE(TM) V Everolimus Eluting Coronary Stent Shows Continued Superiority to TAXUS Stent in Reducing Major Adverse Cardiac Events in SPIRIT III Clinical Trial
2. Spirit II Results Support Strength of Boston Scientifics Two Drug-Eluting Stent Platforms
3. Large Study Gives Nod to Drug-Eluting Stents in Heart Attack
4. Drug-Eluting Stents Outperform Bare Stents in Heart Attack
5. Abbott Announces Positive One-Year Results from the Worlds First Clinical Trial of a Fully Bioabsorbable Drug Eluting Coronary Stent
6. XTENT Announces Positive Two-Year CUSTOM I and One-Year CUSTOM II Trial Data for Novel Drug-Eluting Stent System
7. Four Analyses of Three-Year Clinical Data Suggest CYPHER(R) Sirolimus-Eluting Coronary Stent May Provide Alternative to Surgery for Patients with Multivessel Disease
8. TAXUS WOMAN Study Reports Positive Clinical Outcomes for the TAXUS(R) Drug-eluting Stent in Women
9. Largest Study to Date Shows Significant Reductions in Risks of Blood Clots and Reintervention With CYPHER(R) Sirolimus-eluting Coronary Stent Compared to Taxus Stent
10. Two-Year Outcomes From Large Head-to-Head Clinical Trial Indicate Similar Safety Profile in Diabetic Patients for Cypher(R) Sirolimus-Eluting Coronary Stent and Taxus Stent
11. Cypher(R) Sirolimus-Eluting Coronary Stent Demonstrates Sustained Clinical Benefits Compared to Bare Metal Stents in Five-Year Randomized Clinical Trial With No Differences in Long-Term Safety
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2015)... , Aug. 27, 2015   Proxsys ... Provider (IOPP™) is expanding its population health ... medication-focused transition of care program for hospitals ... Management," provides hospitals with technology systems and ... measures that have been mandated by Center ...
(Date:8/27/2015)... Holdings, Inc., (NYSE: HRC ) invites you to ... Global Healthcare Conference on September 16, 2015, at 11:05 ... to the live discussion via the internet link at ... . A recorded replay of the discussion ... the live event and accessible via the links above. ...
(Date:8/27/2015)... Aug. 27, 2015  BioElectronics Corporation (OTC Pink: BIEL), the ... three abstracts featuring the use of ActiPatch®, its novel ... th Congress of the European Pain Federation EFIC®, ... September 2015. The Company will also be exhibiting at ... Gianluca Bagnato , department clinical and experimental rheumatology from ...
Breaking Medicine Technology:Rx Care Management by Proxsys Rx - Transition of Care Technology Helps Prevent Hospital Medication Errors 2BioElectronics Selected to Present its Pain Research and Devices at the European Pain Federation Conference 2
... When a child is being treated for a serious illness, ... time during long days in the hospital can be extremely challenging. ... from laptops and mobile phones, to video games, movies and music. ... to an already difficult time in a family,s life. ...
... , INDIANAPOLIS, Nov. 16 AMD LASERS, the ... today announced the addition of Bart Waclawik as Chief ... will be responsible for daily global operations, procurement, production, ... Furthermore, he will lead the engineering effort on the ...
Cached Medicine Technology:Children's Hospitals and Clinics of Minnesota Teams With Geek Squad to Open First Ever In-Hospital Precinct 2AMD LASERS Announces the Addition of Bart Waclawik, New Chief Operating Officer 2
(Date:8/27/2015)... ... August 27, 2015 , ... ... scheduled for October 27-29, 2015 in San Jose, CA. The first event ... focus on the void that exists where battery development and energy storage innovation ...
(Date:8/27/2015)... ... , ... In addition to its existing Doctor of Philosophy in Leadership and ... its main campus in Reading: Doctor of Nursing Practice. , Alvernia’s Doctor of ... nurses for the highest level of clinical nursing practice. , “Our vision is ...
(Date:8/27/2015)... ... ... North Pinellas, located at 1395 South Pinellas Avenue in Tarpon Springs, will open a free-standing ... located at US Highway 19 North and Highlands Boulevard, less than eight miles from the ... project is slated to begin in September 2015. , The new 24-bed facility ...
(Date:8/27/2015)... ... August 27, 2015 , ... NetDimensions is once again named ... the platforms required not only to effectively deliver, curate and administer great programs, but ... Inc. , For six consecutive years, NetDimensions has maintained its position on this ...
(Date:8/27/2015)... ... 27, 2015 , ... Z-Medica®, LLC, a leading developer and ... website http://www.Z-Medica.com , to further support the company’s corporate positioning. , The ... , “We launched a branded website last year to show our customers ...
Breaking Medicine News(10 mins):Health News:Infocast Hosting First Conference Dedicated to Powering Wearable Devices & the IoT 2Health News:Alvernia University Now Offering Three Doctoral Degree Programs 2Health News:Florida Hospital North Pinellas is Opening a New Free-Standing Emergency Room in Palm Harbor 2Health News:Florida Hospital North Pinellas is Opening a New Free-Standing Emergency Room in Palm Harbor 3Health News:NetDimensions Named Among Top 20 Learning Portal Companies of 2015 2Health News:NetDimensions Named Among Top 20 Learning Portal Companies of 2015 3Health News:Z-Medica® Launches New Corporate Website 2
... England, both in terms of lives and money nearly ... report published today by the All Party Parliamentary Group (APPG) ... Lives - concludes that, despite effective treatments, there are 365 ... with unnecessary seizures, and 74,000 people are taking anti-epilepsy drugs ...
... tentative agreement with Delmont Laboratory to introduce its immunotherapeutic ... . According to this initial agreement, Delmont Laboratory will ... manufactures for the final packaging in China. ... agreement is to be signed. This product requires a ...
... data from its Phase IIb study in Alzheimer's disease (AD) ... and treated as diabetes of the brain. ... of amyloid beta plaques in the brain, yet recent research ... the brains of mice gives rise to some of the ...
... Diagnostics today announces that it has completed its ... with BioVeris for approximately $600 million on April ... Diagnostics now owns the patents for Electrochemiluminescence (ECL) ... the human diagnostics field into new market segments ...
... confirmed that the potentially lethal H5N1 strain of bird flu ... the country, the second such incident here in a week. ... the area around Frohburg, near Liepzig, second incidence of the ... ,The discovery followed the confirmation on Sunday of ...
... that air pollution affects women more than men . ... groups of mice with pneumonia. One group was exposed ... filtered air. ,The exposure to ozone significantly ... compared to males, reported science portal SCIENCE A GoGo. ...
Cached Medicine News:Health News:Blunders in Epilepsy Care Cost Lives, and Money UK Report 2Health News:Experimental Drug Ketasyn(TM) (AC-1202) Treats Alzheimer's as Diabetes of the Brain 2
Inquire...
Inquire...
Inquire...
... three styles. Each style has multiple sizes. ... popular style. Pectoral Implants are available non-sterile ... individually, not in pairs. Both styles are ... for a specific side and are directional. ...
Medicine Products: